The total number of records retrieved from this search are 20. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
OV_486	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	1 MOI	90% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_490	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	5 MOI	76% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_494	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	10 MOI	58% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_498	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	50 MOI	20% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_502	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Yes	No	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	100 MOI	10% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_506	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	1 MOI	98% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_510	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	5 MOI	76% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_514	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	10 MOI	50% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_518	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	50 MOI	30% cancer cell viability (calculated as relative to mock-infected group), antagonist effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_522	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 0.4 μg/ml ) and doxorubicin (DOX, 0.1 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	100 MOI	16% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_526	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	1 MOI	78% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_530	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	5 MOI	62% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_534	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	10 MOI	44% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_538	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	50 MOI	30% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_542	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 2.0 μg/ml ) and doxorubicin (DOX, 0.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	100 MOI	12% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_546	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	1 MOI	50% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_550	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	5 MOI	42% cancer cell viability (calculated as relative to mock-infected group)	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_554	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	10 MOI	30% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_558	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	50 MOI	21% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624
OV_562	Adenovirus	OBP-301 (telomelysin)	DNA	Adenoviridae	Viral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	No	Viral strain in combination with cisplatin (CDDP, 10.0 μg/ml ) and doxorubicin (DOX, 2.5 μg/ml )	No	Dr. Satoru Kyo (Shimane University, Izumo, Japan)	Human osteosarcoma cell line	SaOS-2	1.0E+3 cells per well	NA	XTT assay	100 MOI	10% cancer cell viability (calculated as relative to mock-infected group), synergistic effect with drugs	No	No	NA	No response	NA	OBP-301-mediated microRNA-29 upregulation suppresses MCL1 expression through E2F1 activation and induces apoptosis	NA	NA	27356624